We can try to achieve controlled, non-invasive, and precise immunotherapy for glioblastomas by expressing Piezo1 on T cells and then locally stimulating glioblastomas using ultrasound or drugs targeting Piezo1, which activates Piezo1 and induces the activation of nuclear factor of t-cells (NFAT), which in turn drives the expression properties of the target genes (Pan et al., 2018). This evidence concerns the gene PIEZO1 and glioblastoma.